Ferric carboxymaltose + ferrous glycine sulphate
ApprovedCompleted 0 watching 0 views this week🔥 Hot
80
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Postoperative Anemia
Conditions
Postoperative Anemia, Osteoarthritis, Knee
Trial Timeline
Jan 1, 2011 → Jan 1, 2013
NCT ID
NCT01913808About Ferric carboxymaltose + ferrous glycine sulphate
Ferric carboxymaltose + ferrous glycine sulphate is a approved stage product being developed by Pharma Mar for Postoperative Anemia. The current trial status is completed. This product is registered under clinical trial identifier NCT01913808. Target conditions include Postoperative Anemia, Osteoarthritis, Knee.
Hype Score Breakdown
Clinical
30
Activity
20
Company
5
Novelty
10
Community
12
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01913808 | Approved | Completed |
Competing Products
20 competing products in Postoperative Anemia